News/ Rare diseases/ US Ionis hit by safety concerns, rivals Alnylam benefit Richard Staines acalabrutinib, Alnylam, Ionis, neurology, Pfizer, Rare diseases 0 Comment Biotech insists drug for rare inherited disorder is still approvable. Share X Ionis hit by safety concerns, rivals Alnylam benefit https://pharmaphorum.com/news/ionis-inotersen-meets-efficacy-targets-fap-safety-concerns-spook-investors/
Cancer/ News AZ confirms move to acquire cancer specialist Acerta Andrew McConaghie acalabrutinib, Acerta, AstraZeneca 0 Comment Acerta brings with it a promising lead candidate Share X AZ confirms move to acquire cancer specialist Acerta https://pharmaphorum.com/news/az-confirms-move-to-acquire-cancer-specialist-acerta/